Arvinas
ARVN

$29.65

1.66%

Market Cap: 2.03B

About: Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Employees: 445

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 16 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

64% more call options, than puts

Call options by funds: $10.3M | Put options by funds: $6.32M

38% more funds holding in top 10

Funds holding in top 10: 8 [Q4 2023] → 11 (+3) [Q1 2024]

29% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 28

22% more repeat investments, than reductions

Existing positions increased: 82 | Existing positions reduced: 67

4% more funds holding

Funds holding: 209 [Q4 2023] → 217 (+8) [Q1 2024]

5% more capital invested

Capital invested by funds: $2.66B [Q4 2023] → $2.78B (+$123M) [Q1 2024]

18.41% less ownership

Funds ownership: 117.58% [Q4 2023] → 99.16% (-18.41%) [Q1 2024]

See Fund Rankings

Research analyst outlook

16 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$52

75%

upside

Avg. target

$72

143%

upside

High target

$90

204%

upside

16 analyst ratings

14 positive

88%

2 neutral

13%

0 negative

0%

HC Wainwright & Co. Andrew Fein	193%upside $87	Buy Reiterated	17 May 2024
Wells Fargo Derek Archila	102%upside $60	Overweight Maintained	9 May 2024
Wedbush Robert Driscoll	75%upside $52	Outperform Reiterated	8 May 2024
Stifel Bradley Canino	129%upside $68	Buy Maintained	8 May 2024
HC Wainwright & Co. Andrew Fein	193%upside $87	Buy Reiterated	8 May 2024

See Analyst Rankings

Financial journalist opinion

Undercovered Dozen: Spirit Airlines, HubSpot, Cigna, First Quantum Minerals +

We share 12 ideas published last week focused on stocks with less coverage on Seeking Alpha. Polestar Automotive Holding is seen as continuing to struggle with missed targets, high losses, and debt raises, warranting a sell. HubSpot faces volatility post-Google acquisition plans, while Grifols considers privatization amid debt concerns and shareholder issues.

Undercovered Dozen: Spirit Airlines, HubSpot, Cigna, First Quantum Minerals +

Zacks Investment Research

Arvinas (ARVN) Surges 9.2%: Is This an Indication of Further Gains?

Arvinas (ARVN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Arvinas (ARVN) Surges 9.2%: Is This an Indication of Further Gains?

Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer

- Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn.

Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer

Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2

– Preclinical data for ARV-393 presented at t he European Hematology Association 2024 Annual Congress showed anti-tumor activity in models of B-cell lymphoma –

Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2

Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D.

NEW HAVEN, Conn., June 17, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced Ian Taylor, Ph.D. has been promoted to President of Research and Development and Angela Cacace, Ph.D. has also been promoted and will succeed Dr. Taylor as Chief Scientific Officer of the company. Dr. Taylor and Dr. Cacace will assume these new roles effective immediately and report to John Houston, Ph.D., Chairperson, President and Chief Executive Officer.

Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D.

Arvinas to Participate in Upcoming Investor Conferences

NEW HAVEN, Conn., June 03, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences:

Arvinas to Participate in Upcoming Investor Conferences

3 Of My Favorite Names On Wells Fargo's Biotech Buyout List

Wells Fargo recently tagged numerous midcap biotech/biopharma stocks as potential buyout targets. There are many names on this list that have been mentioned as acquisition candidates in the past and that could find themselves in Big Pharma's sights. I highlight three of my favorite equities on Wells Fargo's report that I currently hold in my personal accounts in the paragraphs below.

3 Of My Favorite Names On Wells Fargo's Biotech Buyout List

Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress

NEW HAVEN, Conn., May 23, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two abstracts, including one for ARV-766 in prostate cancer and one for TACTIVE-K, a Phase 1b/2 clinical trial with vepdegestrant, a novel investigational oral PROteolysis Targeting Chimera (PROTAC®) ER degrader, in combination with Pfizer's atirmociclib (PF-07220060), an investigational CDK4 inhibitor, were accepted for presentation at the 2024 American Society of Clinical Oncology Annual Congress held May 31 to June 4, 2024, in Chicago, IL.

Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress

Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)

– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in combination with palbociclib were consistent with data previously reported at SABCS in December 2023 –

Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress

NEW HAVEN, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two posters, including updated clinical trial data, for vepdegestrant will be presented at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress held from May 15-17, 2024, in Berlin, Germany. Vepdegestrant is a novel investigational PROTAC® estrogen receptor (ER) degrader that is being jointly developed by Arvinas and Pfizer for the treatment of patients with early and locally advanced or metastatic ER positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer.

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress

See News Rankings